References
-
Horwitz ME, Stiff PJ, Cutler C, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021;138(16):1429-1440.
-
Wei AH, Breccia M, Ooi M, et al. Preliminary results from a phase 1b study exploring MDM2 inhibitor siremadlin (HDM201) in combination with B-cell lymphoma-2 (BCL-2) inhibitor venetoclax in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). Presented December 11, 2021 at the 63rd American Society of Hematology Annual Meeting. Abstract 1283.
-
Pullarkat V, Levis M, Mannis G, et al. Preliminary results by age group of treatment with CPX-351 plus venetoclax in adults with newly diagnosed AML: subgroup analysis of the V-FAST phase 1b master trial. Presented December 11, 2021 at the 63rd American Society of Hematology Annual Meeting. Abstract 1268.
-
Daver N, Aribi A, Montesinos P, et al. Safety and efficacy from a phase 1b/2 study of IMGN632 in combination with azacitidine and venetoclax for patients with CD123-positive acute myeloid leukemia. Presented December 12 at the 63rd American Society of Hematology Annual Meeting. Abstract 372.
-
Garcia-Manero G, Erba H, Sanikommu S, et al. Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine: a phase 1/2 study in patients with myelodysplastic syndrome. Presented December 12, 2021 at the 63rd American Society of Hematology Annual Meeting. Abstract 2601.
-
Advani AS, Moseley A, O’Dwyer KM, et al. A phase 2 study of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia-chromosome (Ph) positive or Ph-like acute lymphoblastic leukemia (ALL) with dasatinib-sensitive fusions/mutations. Presented December 13, 2021 at the 63rd American Society of Hematology Annual Meeting. Abstract 3397.